Roland Bindeus moves from Baxalta to AOP Health – new Head of the Hematology & Oncology Business Unit
Dr Roland Bindeus (38) took control of the Hematology & Oncology Business Unit at the Austrian pioneer of rare diseases, AOP Orphan, at the beginning of April. The biochemist was most recently the general manager of Baxalta Austria, and brings with him ten years of scientific and market experience in the field of rare diseases.
He started his career in the pharmaceutical industry in 2005 at Amgen, where he was particularly involved in the management of clinical studies. In 2008, he moved to Baxter and concentrated on rare diseases in immunological and hematological indications, firstly in the Global Medical Affairs division. He then went on to face the business challenges in this specialized area as Product Manager and Sales & Marketing Manager, further developing close ties to major national and international opinion leaders. Last year, he was given overall responsibility for the Baxalta immunology business in Austria and Switzerland and subsequently for managing the Austrian sales organization so as to develop the local market and organization structure. At AOP Orphan, he will realign the Hematology & Oncology Business Unit, as well as strategically prepare and promote upcoming product launches.
About AOP Orphan
AOP Orphan was one of the first companies to enter the sector of Rare Diseases in Europe and continues to be a trailblazer in the field of Orphan Diseases to this day. The Orphan Diseases specialist researches, produces, and sells innovative solutions, concentrating on three treatment areas: hemotology and oncology, cardiology and pulmonology, and neurology and psychiatry. AOP Orphan is active at an international level with an export ratio of 70% and is one of the leading players in the Orphan Drug market.
AOP Orphan Pharmaceuticals AG
T +43 1 503 72 44-24
F +43 1 503 72 44-61